It is well known that central nervous system (CNS) diseases are the leading cause of the global disease burden. However, although advances in fundamental neuroscience are rapidly accelerating, our understanding of brain function and dysfunction has limited impact on new therapies and treatments for central nervous system diseases. This may be partly because researchers still face a fundamental unanswered question: What constitutes a "good" animal or cell model of neurological disease?
It is indispensable and effective to use animal disease models in experimental medical research. Animal models of neurological disease provide a convenient and reliable platform for developing new therapies and drugs for such diseases. Creative Bioarray uses animal models of different neurological diseases to provide professional drug or therapy testing and research services.
The induction methods of rodent neurological disease models include chemical drugs, surgical induction, and genetic modification. Our pharmacology team has developed a variety of neurological disease models based on the needs of our customers for new drugs or therapy testing.
Our portfolio of neurological disease models cover the following diseases
- Alzheimer's disease
- Parkinson's disease
- Hot-water immersion tail-flick test
- Memory impairment
- Sciatic nerve chronic constriction
- Acetic acid-induced writhing test
- Formalin test
- Spinal cord injury (SCI)
- Primary dysmenorrhea
- Other neurodegenerative diseases
We provide highly customizable services
- Customized animal feeding
- Customized samples collecting
- Biomarker analysis
- Detection of multiple proteins and cytokines
- RNA detection and analysis
- High-throughput sequencing analysis
- Pathology testing
Figure 1. Astrocytic Kir6.1 knockout exacerbates the loss of DA neurons and promotes astrocyte over-activation in SNc of MPTP/p PD model mice. A, Microphotographs of Cresyl violet-positive cells in the substantia nigra compacta (SNc). B, Stereological counts of Cresyl violet-positive cells in the SNc(Hu et al., 2019).
Additionally, our professionals have the expertise and research equipment to study the interaction between the microbiome and metabolic diseases, which attribute critical new aspects to customers' drug development research.
Quotation and Ordering
We have extensive experience in developing disease models based on scientific publications. To discuss any of these models further or to discuss the possibility of developing alternative models, please do not hesitate to contact us.
- Hu, Z.-L.; et al. Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease via promoting mitophagy. Brain, Behavior, and Immunity, (2019), 81, 509–522.
For research use only. Not for any other purpose.